Comparison of Bispecific Antibody Platforms
Several bispecific antibody drugs that have been approved for marketing possess the IgG format, while one (BiTE) consists of two single-chain variable fragments (scFv);
Some bispecific antibodies, generated by linking two different antibody fragments, have structures significantly different from native IgG antibodies, thereby resulting in serious issues of stability and immunogenicity;
The bispecific antibodies developed byAlpHelix, with the native IgG fold, have high stability and low immunogenicity. Therefore, these antibodies are well-suited for further development into therapeutic drugs.
The different structures of bispecific antibodies, in which the approved ones are boxed orange
Alphelix's bispecific antibodies, with an advantage of native IgG fold, are expected to play a significant role in future medication
